Update on mesenchymal stromal cell studies in organ transplant recipients

Sonia Fiori; Giuseppe Remuzzi; Federica Casiraghi

doi:10.1097/mot.0000000000000716

Abstract

1 min read

The available clinical studies in kidney, liver and lung transplantation indicate that autologous and allogeneic MSC therapy from different sources are safe. Now it's time to focus on well-designed efficacy clinical trials, possibly including extensive immunomonitoring.

Related publications

Article2019

Mesenchymal stromal cell-based therapy in kidney diseases and transplantation

Federica Casiraghi, Giuseppe Remuzzi

Article2021

Mesenchymal Stromal Cell Therapy in Solid Organ Transplantation

Manuel Alfredo Podestà, Giuseppe Remuzzi, Federica Casiraghi

Article2018

Long-Term Clinical and Immunological Profile of Kidney Transplant Patients Given Mesenchymal Stromal Cell Immunotherapy

Norberto Perico, Federica Casiraghi, Marta Todeschini, Monica Cortinovis, Eliana Gotti, Valentina Portalupi, Marilena Mister, Flavio Gaspari, Alessandro Villa, Sonia Fiori, Martino Introna, Elena Vittoria Longhi, Giuseppe Remuzzi

Article2019

Mesenchymal Stromal Cells for Transplant Tolerance

Manuel Alfredo Podestà, Giuseppe Remuzzi, Federica Casiraghi

Article2010

Advancement of Mesenchymal Stem Cell Therapy in Solid Organ Transplantation (MISOT)

Martin J. Hoogduijn, Felix Popp, Anja U. Grohnert, Meindert J. Crop, Marieke van Rhijn, Ajda T. Rowshani, Elke Eggenhofer, Philipp Renner, Marlies E. J. Reinders, Ton J. Rabelink, Luc J. W. van der Laan, Frank J. M. F. Dor, Jan N.M. IJzermans, Paul G. Genever, Claudia Lange, Antoine Dürrbach, Jaco H. Houtgraaf, Bruno Christ, Martina Seifert, M. Yu. Shagidulin, Vincent Donckier, Robert Deans, Olle Ringdén, Norberto Perico, ,